Применение индапамида в клинической практике


DOI: https://dx.doi.org/10.18565/therapy.2021.10.188-194

А.В. Сыров

1) ФГАОУ ВО «Российский университет дружбы народов» (РУДН), г. Москва; 2) ГБУЗ «Консультативно-диагностический центр № 6» Департамента здравоохранения города Москвы
Аннотация. Тиазидные/тиазидоподобные диуретики являются средствами первого ряда для лечения артериальной гипертензии. Имеющиеся данные подтверждают снижение заболеваемости и смертности, преимущества контроля объема и натрийуреза, в частности, для снижения риска развития сердечной недостаточности при применении диуретиков. Вместе с тем эта группа включает достаточно разнородные препараты, среди которых особое место занимает тиазидоподобный диуретик индапамид. Оптимальное соотношение эффективности и безопасности делает его препаратом выбора как при монотерапии, так и комбинированной терапии различных групп пациентов с артериальной гипертензией.
Ключевые слова: выбор антигипертензивной терапии, тиазидные и тиазидоподобные диуретики, индапамид
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Клинические рекомендации. Артериальная гипертензия у взрослых. Российское кардиологическое общество. 2020. Рубрикатор клинических рекомендаций Минздрава России. Доступ: www.scardio.ru.

  2. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36(10): 1953–2041. doi: 10.1097/HJH.0000000000001940.

  3. Gabb G.M., Mangoni A.A., Anderson C.S. et al. Guideline for the diagnosis and management of hypertension in adults – 2016. Med J Aust. 2016; 205(2): 85–89. doi: 10.5694/mja16.00526.

  4. Leung A.A., Daskalopoulou S.S., Dasgupta K. et al. Hypertension Canada. Hypertension Canada’s 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017; 33(5): 557–76. doi: 10.1016/j.cjca.2017.03.005.

  5. Task Force of the Latin American Society of Hypertension. Guidelines on the management of arterial hypertension and related comorbidities in Latin America. J Hypertens. 2017; 35(8): 1529–45. doi: 10.1097/HJH.0000000000001418.

  6. Whelton P.K., Carey R.M., Aronow W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018; 71(6): 1269–324. doi: 10.1161/HYP.0000000000000066.

  7. National Clinical Guideline Centre. Hypertension. The clinical management of primary hypertension in adults (NICE clinical guideline 127). London, United Kingdom. 2011. Available at: https://www.nice.org.uk/guidance/cg127 (date of access – 01.12.2021).

  8. Roush G.C., Ernst M.E., Kostis J.B. et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: Antihypertensive and metabolic effects. Hypertension. 2015; 65(5): 1041–46. doi: 10.1161/HYPERTENSIONAHA.114.05021.

  9. Liang W., Ma H., Cao L. et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: A meta-analysis. J Cell Mol Med. 2017; 21(11): 2634–42. doi: 10.1111/jcmm.13205.

  10. Roush G.C., Abdelfattah R., Song S. et al. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2018; 20(10): 1507–15. doi: 10.1111/jch.13386.

  11. Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension. Why select a thiazide-like diuretic? J Hypertension. 2019; 37(8): 1574–86. doi: 10.1097/HJH.0000000000002088.

  12. Suchard M.A., Schuemie M.J., Krumholz H.M. et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet. 2019; 394(10211): 1816–26. doi: 10.1016/S0140-6736(19)32317-7.

  13. Chen Y.J., Li L.J., Tang W.L. et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018; 11(11): CD008170. doi: 10.1002/14651858.CD008170.pub3.

  14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24): 3255–64.

  15. Kostis J.B., Davis B.R., Cutler J. et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997; 278(3): 212–16.

  16. Savage P.J., Pressel S.L., Curb J.D. et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998; 158(7): 741–51. doi: 10.1001/archinte.158.7.741.

  17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981–97. doi: 10.1001/jama.288.23.2981.

  18. Beckett N., Peters R., Tuomilehto J. et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ. 2012; 344: d7541. doi: 10.1136/bmj.d7541.

  19. Beckett N.S., Peters R., Fletcher A. et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887–98. doi: 10.1056/NEJMoa0801369.

  20. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995; 108(9): 710–17.

  21. PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033–41. doi: 10.1016/S0140-6736(01)06178-5.

  22. Bahtiyar G., Gutterman D., Lebovitz H. Heart failure: A major cardiovascular complication of diabetes mellitus. Curr Diab Rep. 2016; 16(11): 116. doi: 10.1007/s11892-016-0809-4.

  23. de Boer I., Bangalore S., Benetos A. et al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273–84. doi: 10.2337/dci17-0026.

  24. Marre M., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004; 22(8): 1613–22. doi: 10.1097/01.hjh.0000133733.32125.09.

  25. Zhang Y., Agnoletti D., Wang J.-G. et al. Natriuresis and blood pressure reduction in hypertensive patients with diabetes mellitus: the NESTOR study. J Am Soc Hypertens. 2015; 9(1): 21–28. doi: 10.1016/j.jash.2014.10.003.

  26. Bangalore S., Fakheri R., Toklu B., Messerli F.H. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016; 352: i438. doi: 10.1136/bmj.i438.

  27. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017; 35(5): 922–44. doi: 10.1097/HJH.0000000000001276.

  28. Wang S., Li J., Zhou X. et al. Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. J Hum Hypertens. 2017; 31(12): 848–54. doi: 10.1038/jhh.2017.51.

  29. Vinereanu D., Dulgheru R., Magda S. et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial. Am Heart J. 2014; 168(4): 446–56. doi: 10.1016/j.ahj.2014.06.010.

  30. Senior R., Imbs J.L., Bory M. et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993; 22 (Suppl 6): S106–S110.

  31. Olde Engberink R.H., Frenkel W.J., van den Bogaard B. et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis. Hypertension. 2015; 65(5): 1033–40. doi: 10.1161/HYPERTENSIONAHA.114.05122.

  32. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. Hypertens. 2015; 33(2): 195–211. doi: 10.1097/HJH.0000000000000447.

  33. Pedersen S.A., Gaist D., Schmidt S.A.J. et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018; 78(4): 673–81.e9. doi: 10.1016/j.jaad.2017.11.042.

  34. Pottegard A., Pedersen S.A., Schmidt S.A.J. et al. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med. 2018; 178(8): 1120–22. doi: 10.1001/jamainternmed.2018.1652.

  35. Lu M., Ma L., Wang X. et al. Indapamide suppresses amyloid-β production in cellular models of Alzheimer’s disease through regulating BACE1 activity. Int J Clin Exp Med. 2017; 10(4): 5922–30.

  36. По данным интернет-порталов apteka.ru, zdorov.ru (дата обращения – 01.12.2021).

  37. Kaplan N.M. Indapamide. Is it the better diuretic for hypertension? Hypertension. 2015; 65(5): 983–84. doi: 10.1161/HYPERTENSIONAHA.115.05138.


Об авторах / Для корреспонденции

Андрей Валентинович Сыров, к.м.н., доцент кафедры общей врачебной практики медицинского института ФГАОУ ВО «Российский университет дружбы народов» (РУДН), зав. отделением кардиологии ГБУЗ «Консультативно-диагностический центр № 6» Департамента здравоохранения города Москвы. Адрес: 117198, г. Москва, ул. Миклухо-Маклая, д. 6. E-mail: syrman2002_1@yahoo.com. ORCID: 0000-0002-2536-5781


Похожие статьи

К содержанию номера

Бионика Медиа